Peptides and Compositions for Treatment of Joint Damage
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 7 of these applications claim priority to application 61/775,400, filed Mar 8, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,745,358 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | Novartis AG | In force | High confidence | ||
| US 10,239,927 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | Novartis AG | In force | High confidence | ||
| US 10,328,126 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | Novartis AG | In force | High confidence | ||
| US 10,533,042 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | Novartis AG | In force | High confidence | ||
| US 11,179,442 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | Novartis AG | In force | High confidence | ||
| US 9,301,971 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | Irm LLC. | In force | High confidence | ||
| US 11,111,283 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | Novartis AG | In force | High confidence | ||
| US 11,370,820 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | Novartis AG | In force | High confidence | ||
| Application 17/453,960 | Peptides and Compositions for Treatment of Joint Damage Abandoned Abandoned Sep 9, 2023 | Novartis AG | Abandoned | Abandoned Sep 9, 2023 | ||
| Application 17/664,810 | Peptides and Compositions for Treatment of Joint Damage Abandoned Abandoned May 31, 2024 | Novartis AG | Abandoned | Abandoned May 31, 2024 |
10 of 10 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
7 of these are in force and held by Novartis AG.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.